{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:05:21Z","timestamp":1789182321619,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03546-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:58:45Z","timestamp":1774335525000},"page":"2001-2017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systematic Literature Review and Meta-Analysis of INSTI-Based Antiretroviral Therapy Single- Versus Multiple-Tablet Regimens for the Treatment of HIV"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7182-4010","authenticated-orcid":false,"given":"Jan","family":"Tuzil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Haloski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seojin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uche","family":"Mordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Dudzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woodie","family":"Zachry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"4","key":"3546_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.35772\/ghm.2023.01013","volume":"5","author":"AK Ghosh","year":"2023","unstructured":"Ghosh AK. Four decades of continuing innovations in the development of antiretroviral therapy for HIV\/AIDS: progress to date and future challenges. Global Health Med. 2023;5(4):194\u20138.","journal-title":"Global Health Med"},{"issue":"suppl 3","key":"3546_CR2","first-page":"24S","volume":"33","author":"J Cutrell","year":"2016","unstructured":"Cutrell J, Bedimo R. Single-tablet regimens in the treatment of HIV-1 infection. Fed Pract. 2016;33(suppl 3):24S\u201330S.","journal-title":"Fed Pract"},{"issue":"2","key":"3546_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/apc.2009.0259","volume":"24","author":"SL Hodder","year":"2010","unstructured":"Hodder SL, Mounzer K, DeJesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1\u2013infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS. 2010;24(2):87\u201396.","journal-title":"AIDS Patient Care STDS"},{"issue":"9","key":"3546_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/cid\/ciu046","volume":"58","author":"JB Nachega","year":"2014","unstructured":"Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297\u2013307.","journal-title":"Clin Infect Dis"},{"key":"3546_CR5","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 17 Oct 2024."},{"key":"3546_CR6","unstructured":"European AIDS Clinical Society. Guidelines, version 12.1. https:\/\/eacs.sanfordguide.com\/. Accessed 5 Feb 2024."},{"key":"3546_CR7","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed 9 Oct 2024."},{"key":"3546_CR8","doi-asserted-by":"crossref","unstructured":"Sweet D, Kim Y, Zhong Y, Zhuo D, Signorovitch J. Real-world adherence among patients receiving single versus multiple tablet regimens for HIV-1 infection, and associations between adherence and viral suppression: a systematic literature review and meta-analysis. Presented at: 20th International AIDS Conference; July 20\u201325, 2014; Melbourne, Australia.","DOI":"10.7448\/IAS.17.4.19537"},{"issue":"1","key":"3546_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","volume":"15","author":"PG Clay","year":"2018","unstructured":"Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17.","journal-title":"AIDS Res Ther"},{"key":"3546_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"3546_CR11","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 9 Oct 2024."},{"issue":"1","key":"3546_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.","journal-title":"Syst Rev"},{"key":"3546_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3546_CR14","unstructured":"Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. https:\/\/www.sheffield.ac.uk\/media\/34225\/download?attachment. Accessed 9 Oct 2024."},{"key":"3546_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2021.107032","volume":"160","author":"MB Mathur","year":"2022","unstructured":"Mathur MB, VanderWeele TJ. How to report E-values for meta-analyses: recommended improvements and additions to the new GRADE approach. Environ Int. 2022;160:107032.","journal-title":"Environ Int"},{"issue":"7109","key":"3546_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"key":"3546_CR17","unstructured":"R Core Team. R: a language and environment for statistical computing. https:\/\/www.R-project.org. Accessed 9 Dec 2024."},{"issue":"7","key":"3546_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/1060028019896638","volume":"54","author":"CG Rodriguez-Gonzalez","year":"2020","unstructured":"Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M. Effectiveness, safety, and costs of dolutegravir\/abacavir\/lamivudine single-tablet regimen in a real-life cohort of HIV-1 adult infected patients. Ann Pharmacother. 2020;54(7):633\u201343.","journal-title":"Ann Pharmacother"},{"issue":"suppl 1","key":"3546_CR19","volume":"27","author":"P Perez Puente","year":"2020","unstructured":"Perez Puente P, Barriga Rodr\u00edguez P, Garrido Ameigeiras MR, Caba Hern\u00e1ndez C. Clinical and economic impact after breaking the single tablet abacavir\/lamivudine\/dolutegravir combo treatment into two drug regimens. Eur J Hosp Pharm. 2020;27(suppl 1):A164.","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"3546_CR20","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"A Avihingsanon","year":"2023","unstructured":"Avihingsanon A, Lu H, Leong CL, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023;10(10):e640\u201352.","journal-title":"Lancet HIV"},{"key":"3546_CR21","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/PPA.S379065","volume":"16","author":"MB Klein","year":"2022","unstructured":"Klein MB, Young J, Ortiz-Paredes D, et al. Virological outcomes after switching to abacavir\/lamivudine\/dolutegravir combined with adherence support in people living with HIV with poor adherence: a phase IV, multicentre randomized prospective open label study (TriiADD-CTN 286). Patient Prefer Adherence. 2022;16:3267\u201381.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3546_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262533","volume":"17","author":"S Degroote","year":"2022","unstructured":"Degroote S, Vandekerckhove L, Vogelaers D, Vanden Bulcke C. Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: data from a real-life setting. PLoS One. 2022;17(1):e0262533.","journal-title":"PLoS One"},{"key":"3546_CR23","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/PPA.S207908","volume":"13","author":"DM Hines","year":"2019","unstructured":"Hines DM, Ding Y, Wade RL, Beaubrun A, Cohen JP. Treatment adherence and persistence among HIV-1 patients newly starting treatment. Patient Prefer Adherence. 2019;13:1927\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3546_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/QAD.0000000000002384","volume":"34","author":"A Chakraborty","year":"2020","unstructured":"Chakraborty A, Qato DM, Awadalla SS, Hershow RC, Dworkin MS. Antiretroviral therapy adherence among treatment-naive HIV-infected patients. AIDS. 2020;34(1):127\u201337.","journal-title":"AIDS"},{"issue":"1","key":"3546_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00268-1","volume":"17","author":"J Cohen","year":"2020","unstructured":"Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res Ther. 2020;17(1):12.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"3546_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0252-z","volume":"19","author":"J Olalla","year":"2018","unstructured":"Olalla J, Perez-Stachowski J, Tortajada B, et al. Efficacy and safety of the switch of Triumeq\u00ae to generic (abacavir + lamivudine) + Tivicay\u00ae: data at 24 weeks. BMC Pharmacol Toxicol. 2018;19(1):63.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"suppl 7","key":"3546_CR27","volume":"23","author":"P Sax","year":"2020","unstructured":"Sax P, Althoff K, Eron J, et al. Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice. J Int AIDS Soc. 2020;23(suppl 7):e25616.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"3546_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107040","volume":"63","author":"A Ciccullo","year":"2024","unstructured":"Ciccullo A, Baldin G, Borghi V, et al. Comparing the efficacy and safety of a first-line regimen with emtricitabine\/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: results from clinical practice. Int J Antimicrob Agents. 2024;63(1):107040.","journal-title":"Int J Antimicrob Agents"},{"key":"3546_CR29","unstructured":"Stellbrink H, Scholten S, Hillenbrand H, et al. Effectiveness, persistence and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF), rilpivirine\/F\/TAF (R\/F\/TAF) or F\/TAF + another 3rd agent in HIV-1 + patients over 24 months \u2013 results from the German TAFNES cohort study. J Int AIDS Soc. 2020;23(suppl 7):e25616."},{"issue":"suppl 3","key":"3546_CR30","first-page":"287","volume":"22","author":"D Mezzio","year":"2021","unstructured":"Mezzio D, Gruber J, Zachry W, Chopra I, Mu Q, Pedarla V. Persistence on guideline-recommended HIV treatment: comparison among US Medicaid beneficiaries newly initiating treatment with single- vs multiple-tablet regimens. HIV Med. 2021;22(suppl 3):287\u20138.","journal-title":"HIV Med"},{"issue":"suppl 1","key":"3546_CR31","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1093\/ofid\/ofaa439.1222","volume":"7","author":"JP Cohen","year":"2020","unstructured":"Cohen JP, Wang X, Wade RL, Cuervo HD, Dionne DM. Persistence of guideline-recommended antiretroviral therapy regimens among persons living with HIV newly initiating treatment in the US. Open Forum Infect Dis. 2020;7(suppl 1):S548\u20139.","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 7","key":"3546_CR32","volume":"23","author":"S Sutton","year":"2020","unstructured":"Sutton S, Wang X, Diaz-Cuervo H, Magagnoli J. Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US. J Int AIDS Soc. 2020;23(suppl 7):e25616.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"3546_CR33","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jiac.2022.07.005","volume":"28","author":"X Wang","year":"2022","unstructured":"Wang X, Schmerold L, Naito T. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan. J Infect Chemother. 2022;28(11):1464\u201370.","journal-title":"J Infect Chemother"},{"issue":"4","key":"3546_CR34","first-page":"410","volume":"27","author":"G Baldin","year":"2019","unstructured":"Baldin G, Ciccullo A, Rusconi S, et al. Single tablet regimen with abacavir\/lamivudine\/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study. Infez Med. 2019;27(4):410\u20134.","journal-title":"Infez Med"},{"key":"3546_CR35","unstructured":"Chastek B, Anderson A, Gruber J. Characteristics, treatment patterns, and virologic outcomes for treatment-experienced people living with HIV switching to MTR or STR ART since 2018. Presented at: 18th European AIDS Conference; October 27\u201330, 2021; Virtual & London, UK."},{"issue":"10\u201311","key":"3546_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/17460794.2024.2403246","volume":"19","author":"A Colson","year":"2024","unstructured":"Colson A, Chastek B, Gruber J, et al. Persistence in treatment-experienced people with HIV switching anti-retroviral therapy regimens since 2018. Future Virol. 2024;19(10\u201311):371\u201380.","journal-title":"Future Virol"},{"issue":"10107","key":"3546_CR37","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382.","journal-title":"Lancet"},{"issue":"1","key":"3546_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","volume":"88","author":"D Hagins","year":"2021","unstructured":"Hagins D, Kumar P, Saag M, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study. J Acquir Immune Defic Syndr. 2021;88(1):86\u201395.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"3546_CR39","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","volume":"73","author":"PE Sax","year":"2021","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73(2):e485\u201393.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3546_CR40","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/QAD.0000000000002244","volume":"33","author":"G Rizzardini","year":"2019","unstructured":"Rizzardini G, Gori A, Miralles C, et al. Randomized study evaluating the efficacy and safety of switching from an abacavir\/lamivudine-based regimen to an elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide single-tablet regimen. AIDS. 2019;33(10):1583\u201393.","journal-title":"AIDS"},{"key":"3546_CR41","unstructured":"Orkin C, Antinori A, Rockstroh J. Outcomes after switching from 144 weeks of blinded DTG\/ABC\/3TC or DTG+F\/TAF to 96 weeks of open-label B\/F\/TAF. Presented at: HIV Glasgow; October 23\u201326, 2022; Glasgow, UK."},{"key":"3546_CR42","unstructured":"Pozniak A, Maggiolo F, Podzamczer D, et al. Outcomes 48 weeks after switching from TG\/ABC\/3TC or DTG+F\/TAF to B\/F\/TAF. Presented at: 8th European AIDS Conference; October 27\u201330, 2021; Virtual & London, UK."},{"issue":"6","key":"3546_CR43","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"HJ Stellbrink","year":"2019","unstructured":"Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364\u201372.","journal-title":"Lancet HIV"},{"issue":"6","key":"3546_CR44","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389-400.","journal-title":"Lancet HIV"},{"issue":"1","key":"3546_CR45","first-page":"168","volume":"28","author":"A Mills","year":"2020","unstructured":"Mills A, Gupta SK, Brinson C, Workowski K, Clarke A, Antinori A. 144-week efficacy and safety of B\/F\/TAF in treatment-naive adults \u226550 yrs. Top Antivir Med. 2020;28(1):168.","journal-title":"Top Antivir Med"},{"issue":"7","key":"3546_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25758","volume":"24","author":"I Su\u00e1rez-Garcia","year":"2021","unstructured":"Su\u00e1rez-Garcia I, Alejos B, Ruiz-Alguer\u00f3 M, et al. Effectiveness and tolerability of dolutegravir and abacavir\/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain. J Int AIDS Soc. 2021;24(7):e25758.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"3546_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107016","volume":"63","author":"D Corona","year":"2024","unstructured":"Corona D, Perez-Valero I, Camacho A, et al. Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV late presenters. Int J Antimicrob Agents. 2024;63(1):107016.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"3546_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/hiv.12701","volume":"20","author":"HB Krentz","year":"2019","unstructured":"Krentz HB, Campbell S, Lahl M, Gill MJ. De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings. HIV Med. 2019;20(3):214\u201321.","journal-title":"HIV Med"},{"issue":"5","key":"3546_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jmii.2023.07.013","volume":"56","author":"GJ Chen","year":"2023","unstructured":"Chen GJ, Sun HY, Chang SY, et al. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound. J Microbiol Immunol Infect. 2023;56(5):988\u201395.","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"3546_CR50","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/QAD.0000000000003480","volume":"37","author":"C Bowman","year":"2023","unstructured":"Bowman C, Ambrose A, Kanitkar T, et al. Real world use of dolutegravir two drug regimens. AIDS. 2023;37(5):785\u20138.","journal-title":"AIDS"},{"issue":"42","key":"3546_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001677","volume":"94","author":"PG Clay","year":"2015","unstructured":"Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42):e1677.","journal-title":"Medicine (Baltimore)"},{"issue":"suppl 2","key":"3546_CR52","first-page":"1","volume":"16","author":"A Hill","year":"2015","unstructured":"Hill A, Pozniak A, Simmons B. No difference in risk of virological failure between antiretroviral treatments using co-formulated versus individual drugs: meta-analysis of 9 randomised trials in 2,568 patients. HIV Med. 2015;16(suppl 2):1\u201311.","journal-title":"HIV Med"},{"issue":"5","key":"3546_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/tmi.12297","volume":"19","author":"R Ramjan","year":"2014","unstructured":"Ramjan R, Calmy A, Vitoria M, et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health. 2014;19(5):501\u201313.","journal-title":"Trop Med Int Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03546-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:28:32Z","timestamp":1778581712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03546-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3546"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03546-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jan Tuzil, Krzysztof Lach, and Mirella Dudzic are employees of Maple Health Group, which received funding from Gilead Sciences, Inc., in connection with this research. Mary J. Christoph, Megan Chen, Kristen Haloski, Uche Mordi, and Woodie Zachry are employees and stockholders of Gilead Sciences, Inc. Seojin Park was an employee and stockholder of Gilead Sciences, Inc., at the time the study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}